2026-10-14T13:57:11Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34047247 2026-10-01T17:04:51Z category_4 category_7 category_8 category_12 category_15 category_19 category_21 category_873 category_45 category_64 category_132 portal_87 item_type_6 month_year_10_2026

Pharmacokinetic comparisons between liposome formulation and non-liposome formulation of omega-3 fatty acids: a randomized clinical study Yun Seob Jung (25157536) Ae Gyeoing Im (25157539) Sung Dae Kwon (25157542) Tae Gi Kim (6693977) Dong Woo Chae (25157545) Biochemistry Medicine Microbiology Cell Biology Neuroscience Pharmacology Biotechnology Chemical Sciences not elsewhere classified Sociology Cancer Infectious Diseases Liposome omega-3 fatty acid extent of absorption eicosapentaenoic acid docosahexaenoic acid <p>Liposomal delivery systems may enhance the systemic exposure of lipophilic nutrients. This study evaluated the effect of a liposomal omega-3 formulation (Liposomal ABMax Omega-3) on the extent of absorption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) compared with conventional ethyl ester (EE) and re-esterified triglyceride (rTG) formulations. In a randomized, double-blinded, parallel, active-controlled clinical study, 45 healthy adults received a single oral dose of (1,800 mg total) liposomal omega-3 (Liposomal ABMax Omega-3), EE omega-3, or rTG omega-3. Baseline-corrected serum concentrations of EPA and DHA were measured up to 24 h post-dose. Pharmacokinetic parameters were derived using noncompartmental methods, with incremental AUC (iAUC) as the primary endpoint. Liposomal omega-3 (Liposomal ABMax Omega-3) resulted in significantly higher baseline-corrected iAUC for DHA and EPA+DHA than the conventional EE and rTG formulations. No clinically significant safety concerns were identified. Liposomal formulation significantly enhanced systemic exposure of EPA and DHA compared with conventional formulations, supporting its potential to improve systemic exposure. These findings support that liposomal omega-3 (Liposomal ABMax Omega-3) enhances the systemic exposure of EPA and DHA and shows good tolerability within body.</p> <p>This study was registered with the Clinical Research Information Service (KCT 0011550).</p> 2026-10-01T17:04:51Z Text Journal contribution 10.6084/m9.figshare.34047247.v1 https://figshare.com/articles/journal_contribution/Pharmacokinetic_comparisons_between_liposome_formulation_and_non-liposome_formulation_of_omega-3_fatty_acids_a_randomized_clinical_study/34047247 CC BY 4.0